Correspondance to: Ola Nakken, email: ola.nakken@medisin.uio.no, telephone +4797659796, 95% CI 1.6-2.0) than for mortality (1.5; 95% CI 1.2-1.8) (p=0.04). There were also significant regional differences in prevalence (p<0.01) but not in mortality.
Introduction
Amyotrophic lateral sclerosis (ALS) mortality is increasing within the Norwegian aging population (1) . Whereas no nationwide prevalence study has been conducted in Norway, studies based solely on hospital records in two single counties found prevalence rates of 3.67/100,000 on 31 st December 1988 (2) and 4.06/100,000 on 31 st December 2007 (3).
In Europe, reported ALS prevalence ranges from 1.1/100,000 in former Yugoslavia (4) to 10.3/100,000 in the Netherlands (5) . Methods of data collection differ across studies.
Combining multiple data sources is generally considered the best strategy (6, 7) . Whilst dedicated ALS-register data have the advantage of case ascertainment of high validity, population based prevalence estimates from national compulsory health registers can provide nationwide data in a clinically relevant setting.
Norway has a relatively stable population and equal access to health care. There are public hospitals with neurological services in all counties where ALS patients are diagnosed and typically followed every third month, and medical care including prescription drugs are provided free of charge above a yearly threshold of 237 Euro (8) . All drug prescriptions, diagnoses from public and private specialist health care, and causes of deaths are registered in compulsory health registers. The registers have been operating for several years and can be linked through a unique identification number, allowing prevalence estimates of potentially high accuracy (9) . The aim of this study was to combine these registers to determine the prevalence of ALS in Norway from 2009 to 2015.
Materials and Methods
Data were extracted from the Norwegian Patient Registry (NPR), the Norwegian Prescription (11) . The identity of all deceased patients identified in this process was sent to NPR to assess the completeness of the registry. We also reviewed hospital files of patients coded as G12.8 and G12.9 (unspecified/other spinal muscular atrophies) to evaluate the specificity of these diagnoses and how often these were reclassified as ALS. Ultimately, to assess whether the diagnostic accuracy in the two university hospitals were representative for the country as a whole, we asked NPR to quantify the number of individuals first coded as G12.8/G12.9 and later as G12.2.
Case definitions and Analyses
For our main prevalence estimates we used the following ALS case definition;
 Alive at prevalence date, minimum one entry in at least two of three registers (riluzole dispense in NorPD, G12.2 in NPR/NCoDR; at least one prior to prevalence date).
or  Alive at prevalence date, minimum two G12.2 entries in NPR, at least one of these prior to prevalence date, and first entry no more than four years prior to prevalence date.
Prevalence was calculated as the number of patients satisfying our case definition every 31 st December from 2009 until 2015, divided by the corresponding total population in Norway.
Ninety-five % confidence intervals (CI) for proportions were calculated by the exact method.
Poisson regression with robust variance (12) was fitted for prevalence ratios, time trends and possible interactions. Independent variables in the model included gender, age as first and second degree term, prevalence year, and was extended with health regions and interaction terms for regional rate ratios and annual change in national prevalence or gender ratio,
respectively. Similar models were fitted for mortality data only, enabling comparison of rate ratios between prevalence and mortality data. Wald test was used to determine whether there were differences in prevalence between health regions, and in addition regional rates were internally standardized by the direct method for comparison. A continuous age variable was constructed by subtracting median birth year from prevalence year, and from this we calculated mean age. A linear regression model with gender, prevalence year, interaction between the two and mean age in the total population was fitted for analyses of mean age trends and differences. We used chi square to test for gender differences in riluzole use. The statistical software Stata (Version 14.2, StataCorp LP, TX, USA) was used for all analyses.
Results

Validation
We first tested the accuracy of ALS diagnoses by reviewing the hospital files at Akershus Ten of these fulfilled the Awaji criteria for ALS, and another four later developed ALS.
Twelve out of these 14 cases were however coded twice or more as G12.2 during the study period, and therefore not missed in the study. At a country level, a total of 63 individuals initially coded as G12.8 or G12.9 were later coded twice as G12.2 in NPR.
The consistency between register entries are displayed in supplementary Table 1 .
Because of legal constraints and privacy concerns, direct validation of NorPD is difficult.
However, of the 1216 cases with at least two G12.2 entries in NPR (constricted as in the main case definition), 944 (78 %) were retrieved with ever riluzole dispense in NorPD. For NCoDR, the corresponding proportion was 687 out of 971 (71 %).
ALS prevalence
We Figure 1 and Table 1 ). There were no longitudinal trends (p=0.98). The male: female gender ratio ranged from 1.6 to 2.0 (Table 1) , also without any changes throughout the study period. Females tended to be older than males (1.6 years; p=0.14). Longitudinally, mean age increased for females, different from no change among males (p=0.01). Of the 882 male cases identified through either NCoDR or within the NPR main case definition subgroup, 73 % had ever dispensed riluzole.
Amongst the 637 females, the corresponding proportion was 68% (p=0.02). Amongst those found in NCoDR, mortality rates were calculated from 2009 to 2015. Within this period, there was no significant trend in mortality rates. The mean male: female ratio was 1.5 (95 % CI 1.2-1.8) for mortality and 1.8 (95 % CI 1.6-2.0) for prevalence (p=0.04).
( Table 1 near 
Contribution from different registers
Figure 2 displays how the registers contributed to the prevalence estimates based on our main case definition throughout the study period. As expected, in the first part of the period most patients were registered in both NPR and NCoDR, whereas NorPD became increasingly important at the end of the study. As our latest prevalence date coincided with NCoDRs final recording, no cases could be ascertained from NCoDR at this date. The proportion of cases ascertained exclusively through NPR increased throughout the study period, compensating the declining contribution from NCoDR, and also reducing the proportion of those depending on riluzole dispense.
( Figure 2 near here)
Regional, gender and age distribution
There were significant differences in prevalence between the four health regions (p<0.01) ( Table 2) . A post hoc analysis showed that prevalence rates were 19 % greater in Region West (p<0.01) compared to South-East, with 20 % more men (p=0.07). Region Middle and North did not differ significantly from South-East with regards to prevalence rates or gender ratio.
No geographical differences in rates or gender ratios were seen when analysing mortality data (NCoDR) separately.
( Table 2 near here) Figure 3 displays age distribution by gender. The age group with highest prevalence amongst both genders was 70-79 years. There were more males than females in every age group.
Prevalence dropped amongst the highest age groups in both genders.
( Figure 3 near here)
Discussion
By combining three compulsory health registers, we found a stable prevalence of ALS in
Norway from ultimo 2009 to ultimo 2015. The estimated prevalence was almost twice as high as previously reported in single counties (2, 3) , with significant regional and gender inequalities. ALS prevalence estimated in other European studies conducted retrospectively display great variability (4-11/100,000) (13) (14) (15) (16) (17) (18) (19) (20) . Reports based on European prospective population based ALS-registers are more uniform (7-9/100,000) (21) and concur with our estimates. The difference in ALS prevalence between the present and previous studies exceeds the modest increase in incidence suggested by mortality (1) . This discrepancy may be due to methodological differences, as previous studies were based solely on hospital files (2, 3). Although prevalence did not change during our limited observation period, we cannot exclude that also increased survival has contributed to increased prevalence. No disease modifying agent has been introduced in Norway since riluzole in 1996 (22) . The use of riluzole did not change during the study period (23). The use of mechanical ventilation amongst ALS-patients is however increasing (24, 25) , and has a substantial effect on survival (26) . Increased awareness and changes in diagnostic practice, including genetic testing, could also impact prevalence estimates (27) . In Norway there seems to be a clustering of familial ALS with the SOD1 H46R mutation (28, 29) . These patients generally have long survival (30) , and may therefore have substantial impact on prevalence rates despite being relatively few.
The male: female ratio for mortality in our study (1.5) was consistent with that reported previously for incidence rate (1.4) in Europe (31). The gender ratio for prevalence (1.8) was however higher, suggesting that males live longer with the diagnosis. Similar gender differences for ALS survival have been reported previously (32) . Independent factors such as young age, spinal onset, the diagnosis of "possible ALS" and symptoms having started more than 12 months prior to diagnosis predict longer survival (32) . Of these, we were only able to register age, crudely derived from birth cohorts and prevalence year. Although generally younger males support this coherence, gender differences in adopting therapeutic measures and life-sustaining interventions such as riluzole, percutaneous gastrostomy, and mechanical ventilation also could influence survival. Indeed, we found that more men than women had dispensed riluzole. Moreover, data from the Norwegian Mechanical Ventilation
Register has shown that more men (70%) than women (30%) used long term mechanical ventilation (25) . For either of the treatments, our data cannot separate if the observed gender difference is due to patients' or physicians' preferences. It is possible that distinctive gender roles make females more inclined to accept either their own disease course, or to accept the nursing role for their sick spouses (33) .
We found differences in ALS prevalence between health regions. Similar geographical differences were not found for mortality. Although the latter analysis was performed post hoc and the discrepancy in regional prevalence versus mortality is uncertain, it may indicate differences in survival. Environmental factors such as smoking and low socioeconomic status have been linked to short survival (34), but we are not aware of such regional differences in
Norway. Whereas the use of riluzole seems to be very similar across Norway (23), an earlier report revealed regional differences in adopting long term mechanical ventilation (35). The regional differences in the use of mechanical ventilation did however not correspond to those observed for ALS prevalence, and can therefore not explain these. It should be noted that even small differences in the timing of the diagnostic workup could have substantial impact on prevalence rates, and that the health region with highest ALS prevalence was the first to invent a multidisciplinary ALS team in Norway (36) .
There are several pitfalls when using automated hospital discharge and prescription data in epidemiological studies, including errors due to misclassification (37) . When evaluating hospital files we found that 11 % of those who were encoded G12.2 once, and 3% of those encoded G12.2 twice, did not have ALS. As these misclassified cases generally had diseases with longer life expectancy than in ALS they would accumulate in NPR over time.
Requiring entry in two separate registers would prevent this. However, as a substantial proportion of our patients were either not deceased (increasingly towards the end of our study period), or in line with previous reports had not dispensed riluzole (13, 38) , it would underestimate prevalence. To avoid both these pitfalls, we decided that to be included solely based on two or more entries in NPR, the first entry had to be no more than four years prior to prevalence date. This criterion does not allow cases misclassified as ALS to accumulate over time, and thereby restricts the overestimation to approximately 3% throughout the study period. Because the vast majority of ALS patients will meet a specialist more than once and does not survive beyond four years, it would nevertheless catch most living cases not using riluzole, who would otherwise be lost. Our main case definition therefore included patients either fulfilling this criterion, or registered in two separate registers.
There is a possibility that patients with ALS were not given correct ICD-code (negative misclassification) both in NPR and NCoDR, leading to under ascertainment. From our hospital records, such cases were however very few. It is however possible that we have missed some ALS patients with long survival and rare visits to neurologists, particularly if these do not use riluzole. Some patients with H46R SOD1 mutation might fall into this category (29) . Also some ALS patients living in nursing homes could be missed, as severe disability might prevent them from seeing a specialist regularly, and NorPD only collects data from drugs dispensed in pharmacies.
Although each register is compulsory, neither of them was redundant in this study.
Because the first prevalence date was set only two years after NPRs first recording, some prevalent cases could have been missed in this registry at this date. NCoDR and NorPD could however catch these cases. NCoDR would obviously gradually lose relevance in recent time,
and it is also necessary to combine this registry with other data sources to identify when each case became incident. Although the use of several registers allows verification of the diagnosis and the incidence year, the changing contribution from each register during the study period could potentially disguise a true change in ALS prevalence. Furthermore, the validation of our main case definition relies much on hospital files at two university hospitals.
Although neurological services are rather homogenous throughout Norway, we cannot rule out that the diagnostic accuracy at these hospitals do not represent the country as a whole. Our evaluation of reclassified cases however crudely indicates such proportionality.
In conclusion, combining three compulsory health registers in Norway reveals that ALS prevalence remained stable from 2009 to the end of 2015, at a level consistent to other European countries and considerably higher than reported in previous studies based solely on hospital records. Our data also reveal differences in prevalence between genders and regions that are not likely explained by differences in incidence. It is known that males are more likely to use mechanical ventilation, and we here show that males also are more likely to use riluzole. These inequalities need to be further explored.
